AbbVie IncNYSE:ABBV
- LAST PRICE167.4400
- TODAY'S CHANGE (%)-2.9300 (-1.7198%)
- Bid / Lots167.4300/ 2
- Ask / Lots167.5400/ 1
- Open / Previous Close168.6300 / 170.3700
- Day Range
- 52 Week Range
- Volume195,355
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ABBV |
|---|---|---|
| 09:32 ET | 3019 | 168.5 |
| 09:34 ET | 119992 | 168.22 |
| 09:36 ET | 21129 | 167.54 |
| 09:38 ET | 8432 | 167.56 |
| 09:39 ET | 7851 | 167.44 |
Today
AbbVie to Host Second-Quarter 2024 Earnings Conference Call, from 1 hour ago by Dow Jones
1 hour ago by Dow Jones
Yesterday
Robert A. Michael Assumes Role as AbbVie Chief Executive Officer, from 8:00AM ET on Monday Jul 01, 2024 by Dow Jones
8:00AM ET on Monday Jul 01, 2024 by Dow JonesPress Release: Robert A. Michael Assumes Role as AbbVie Chief Executive Officer, from 8:00AM ET on Monday Jul 01, 2024 by Dow Jones
8:00AM ET on Monday Jul 01, 2024 by Dow Jones
Jun 28, 2024
Jun 27, 2024
DJ AbbVie Buys Celsius Therapeutics for $250 Million, from 9:43AM ET on Thursday Jun 27, 2024 by Dow Jones
9:43AM ET on Thursday Jun 27, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
AbbVie Inc | 300.9B | 49.9x | -6.05% |
Merck & Co Inc | 323.9B | 143.2x | -43.23% |
AstraZeneca PLC | 241.2B | 38.0x | +17.52% |
Novartis AG | 234.6B | 24.1x | -5.59% |
Roche Holding AG | 228.0B | 17.4x | +3.28% |
Pfizer Inc | 159.9B | -462.9x | -7.10% |
Company Information
AbbVie Inc. is a diversified research-based biopharmaceutical company. The Company is engaged in the research and development, manufacturing, commercialization and sale of medicines and therapies. It offers products in therapeutic categories, including immunology, which include Humira, Skyrizi and Rinvoq; oncology, which include Imbruvica, Venclexta/Venclyxto, Epkinly and Elahere; aesthetics products, which include Botox Cosmetic, The Juvederm Collection of Fillers and others; neuroscience, which include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy and Qulipta; eye care, which consists of Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other products, which include Mavyret/Maviret, Creon, Lupron, Linzess/Constella and Synthroid. It offers NX-13, a first-in-class, oral NLRX1 agonist, for the treatment of ulcerative colitis (UC) and Crohn's disease (CD). It also offers CEL383, a first-in-class anti-TREM1 antibody, for the treatment of inflammatory bowel disease.
Contact Information
- Headquarters
- 1 N Waukegan RdNORTH CHICAGO, IL, United States 60064
- Phone
- 847-932-7900
- Fax
- 302-655-5049
Executives
- Executive Chairman of the Board
- Richard Gonzalez
- Chief Executive Officer, Director
- Robert Michael
- Chief Financial Officer, Executive Vice President
- Scott Reents
- Chief Human Resource Officer, Executive Vice President
- Timothy Richmond
- Executive Vice President, General Counsel, Company Secretary
- Perry Siatis
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $300.9B |
|---|---|
Revenue (TTM) | $54.4B |
Shares Outstanding | 1.8B |
Dividend Yield | 3.70% |
Annual Dividend Rate | 6.2000 USD |
Ex-Dividend Date | 07-15-24 |
Pay Date | 08-15-24 |
Beta | 0.62 |
EPS | $3.36 |
Book Value | $5.87 |
P/E Ratio | 49.9x |
Price/Sales (TTM) | 5.5 |
Price/Cash Flow (TTM) | 20.5x |
Operating Margin | 23.50% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
